Figure 1.

MARCH1 was highly expressed in the human hepatocellular carcinoma (HCC) tumour samples and cell lines (Hep3B and HepG2). A, Immunohistochemistry (IHC) analyses showing increased MARCH1 expression in liver tissue from patients with HCC compared with adjacent non‐tumour (NT) liver tissue; and the IHC score of MARCH1 in 14 cases. B, Western blotting assay showing the expression of MARCH1 in the four cell lines. C and D, Western blotting analysis was used to assay the interference efficiency of the two sequences of MARCH1 siRNA in the HepG2 and Hep3B cells for 48 h. E and F, Western blotting assay showed the MARCH1 protein levels in the HepG2 and Hep3B cells treated with pirarubicin (THP) for 24 h and 48 h in different concentrations, respectively. All the data in this figure are represented as mean ± SD. *P < 0.05